A detailed history of Fox Run Management, L.L.C. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 19,263 shares of ITOS stock, worth $158,534. This represents 0.05% of its overall portfolio holdings.

Number of Shares
19,263
Previous 12,018 60.28%
Holding current value
$158,534
Previous $178,000 10.11%
% of portfolio
0.05%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.09 - $17.97 $73,102 - $130,192
7,245 Added 60.28%
19,263 $196,000
Q2 2024

Aug 13, 2024

SELL
$10.33 - $18.09 $29,192 - $51,122
-2,826 Reduced 19.04%
12,018 $178,000
Q1 2024

May 13, 2024

SELL
$9.89 - $13.64 $127,709 - $176,133
-12,913 Reduced 46.52%
14,844 $202,000
Q4 2023

Feb 13, 2024

BUY
$8.57 - $11.06 $237,877 - $306,992
27,757 New
27,757 $303,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.